ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

EVG Evgen Pharma Plc

0.80
0.00 (0.00%)
30 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.80 0.75 0.85 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 422k -4.04M -0.0147 -0.54 2.2M
Evgen Pharma Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker EVG. The last closing price for Evgen Pharma was 0.80p. Over the last year, Evgen Pharma shares have traded in a share price range of 0.75p to 4.05p.

Evgen Pharma currently has 274,888,117 shares in issue. The market capitalisation of Evgen Pharma is £2.20 million. Evgen Pharma has a price to earnings ratio (PE ratio) of -0.54.

Evgen Pharma Share Discussion Threads

Showing 7651 to 7674 of 13025 messages
Chat Pages: Latest  317  316  315  314  313  312  311  310  309  308  307  306  Older
DateSubjectAuthorDiscuss
09/3/2021
08:30
Another c40% of shareholding disclosures to come and a raft of potential positive newsflow from Huw at anytime....the only way is UP!!! Gla :-)
moneymunch
08/3/2021
14:06
Brasso - not much to say when there’s nothing to comment on, just waiting for the news flow to commence.
bumpa33
08/3/2021
14:04
Apologies, thought they’d decreased.
bumpa33
08/3/2021
13:53
This one is an increase despite the RNS showing a lower % (due to the placing).
As of 9/10/20 they held 5.9M shares (still there on Evgen webpage), now they hold 8.3M, an increase of 2.4M shares

on target
08/3/2021
13:53
Bumpa

You have been a stranger on here. :)

brasso3
08/3/2021
13:52
There go the Newlands, I don’t know how the hell they keep tabs on all their holdings - they’re in bloody everything.
bumpa33
08/3/2021
13:48
Nice one clocktower....Perfect timing.:-)
moneymunch
08/3/2021
13:44
Today, looked like a good time to join the club.
clocktower
08/3/2021
13:37
Last time we'll see sub 8p I reckon...more disclosures to come and news from Huw at anytime in the coming days and weeks. Gla :-)
moneymunch
08/3/2021
12:36
If there are 100 investors with one nominee account and they all hold the same number of shares, if 90 of them do not subscribe and 10 do in theory you can get 10 times your allocation.
brasso3
08/3/2021
12:33
Maybe, but won't the nominee then scale back individual holders the same %?
on target
08/3/2021
12:27
You should get about 50% of your excess shares application, assuming they scale everyone back by the same amount.
on target
08/3/2021
12:22
Plenty picking them up at the 8p placing price this morning, me included.
on target
08/3/2021
12:13
It seems to have pulled demand away as investors are waiting to see what they got allocated and also have the funds tied up.
brasso3
08/3/2021
10:37
Yep, I'm still waiting too, it can take up to 2 weeks according to the corporate action details on my account.
moneymunch
08/3/2021
10:11
I still do not have my funds back from HSDL. I imagine a lot are in this position with money tied up.
brasso3
08/3/2021
07:56
Hi Nobby, please can I have a coin for the guild? Thanks in advance.
raldo
07/3/2021
22:24
Dr Huw Jones, Evgen CEO, commented: "We are pleased to see such progress on a potential vaccine against COVID-19. Recently ARDS has been heavily associated with COVID-19 as it affects the respiratory tract, but it is and will remain a condition in its own right long after we have beaten the pandemic and will continue to be a huge problem for patients. There is a considerable unmet need for effective treatments for ARDS and the outcome of our study will hopefully show how we can use SFX-01 in a serious respiratory condition regardless of the infective agent involved."
moneymunch
07/3/2021
22:21
The UK must prepare for a "hard winter" because the population immunity to respiratory viruses other than Covid could be lower than usual, one of England's top medics has warned.

Dr Susan Hopkins said the NHS must be "ready" for surges in flu and other similar illnesses.

It comes ahead of England's first step towards easing lockdown, with all pupils returning to school on Monday.

Most pupils have been learning from home since Christmas.

Dr Hopkins, who is in charge of Public Health England's Covid strategy, said the UK needed to be "better prepared" than it was last autumn, when new, faster-spreading variants of the virus emerged.

These drove infection rates up and forced further lockdown measures over the winter.

Dr Hopkins told the BBC's The Andrew Marr Show: "I think we have to prepare for a hard winter, not only with coronavirus, but we've had a year of almost no respiratory viruses of any other type. And that means, potentially the population immunity to that is less.

"So we could see surges in flu. We could see surges in other respiratory viruses and other respiratory pathogens."

Dr Hopkins said her role as a government advisor was to "prepare for worst-case scenarios".

moneymunch
07/3/2021
21:15
Another 40% plus of shareholding disclosures to come and so every chance of another Major player or two to join the party. DSBM's assessment on the first 60 SFX-01 Covid/Ards patients expected early Q2, ie next month, and so I reckon Huw could have an update or two before that, on the SHP2 cancer target and also the Glioblastoma target and maybe even an update on the breast cancer programme....Exciting times for all invested....there's not many other Bio's around, fully funded with so many shots on multiple targets attracting investment from the leading players in the market....all for 8p a share!!!???? :-)))
moneymunch
07/3/2021
20:58
Ps a Big Thank You to the person who awarded 70 plus coins to the thread, very much appreciated....On and UP!!! :-)
moneymunch
07/3/2021
15:36
Octopus have got an exceptional track record, they're the UK's leading VC with over £9.1 Billion managed funds, and two Directors bought in, Huw had another 65k and Sue Fodin bought 125k, but obviously all Directors have Share Options in place and so have plenty of incentives to increase the share price and value of the company. They've actually raised £11m on top of the c£2m cash in the bank, and i'd suggest that they're extremely bullish, given that they have multiple shots on multiple targets, anyone of which could provide transformational upside on success, and i personally can't think of many other Bio's in a similar position with a similar value. There's a raft of potential positive news to drive the share price upwards that Huw could deliver in the coming weeks and months and so a fully funded Evgen with multiple prospects and potential, makes for a very attractive investment imho.....this will move big just as soon as the placing dust settles, and look forward to more shareholding disclosures in the coming days. Gl ;-)
moneymunch
07/3/2021
15:13
Has octopus a good track record ?I'm long at 8p and a decent position I'm not bearish BUT No director buying worries me AND why raise 13m when 5m was all that was wanted initially ?Make me wonder how bullish they actually are
nico115
07/3/2021
14:42
Lol nico, Octopus is the most powerful VC fund in the UK, the market leader, and so their investment here speaks volumes imho and a strong show of confidence in Evgen's prospects and potential, and somewhat amusing that you think that Evgen has raised too much cash, they now have around c£13m cash to accelerate development of their multiple disease target pipeline, a substantial amount commensurate to their current £21m market cap, especially compared to other Bio's worth several hundred millions more, that aren't much more advanced and have less targets than Evgen.....let's see what other share disclosures arrive, and let's wait for Huw to update the market on progress and devlopments on Evgen's undoubted transformational potential....which are up there with the best, and the very reason why Octopus has take 7.9%.....Exciting times for those invested. Gl ;-)
moneymunch
Chat Pages: Latest  317  316  315  314  313  312  311  310  309  308  307  306  Older

Your Recent History

Delayed Upgrade Clock